Edition:
United Kingdom

Aquinox Pharmaceuticals Inc (AQXP.OQ)

AQXP.OQ on NASDAQ Stock Exchange Global Market

2.29USD
8:59pm GMT
Change (% chg)

$0.01 (+0.44%)
Prev Close
$2.28
Open
$2.27
Day's High
$2.31
Day's Low
$2.26
Volume
19,983
Avg. Vol
40,149
52-wk High
$16.85
52-wk Low
$1.98

Latest Key Developments (Source: Significant Developments)

Aquinox Pharmaceuticals Inc - Aquinox's headcount for 2019 will be reduced to eight
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Aquinox Pharmaceuticals Inc ::AQUINOX PHARMACEUTICALS INC - AQUINOX'S HEADCOUNT FOR 2019 WILL BE REDUCED TO EIGHT.AQUINOX PHARMACEUTICALS INC - ON NOVEMBER 6, 2018, AQUINOX'S BOARD OF DIRECTORS APPROVED FURTHER RESTRUCTURING TO REDUCE OPERATING COSTS.AQUINOX PHARMACEUTICALS INC - ALL RESEARCH AND DEVELOPMENT ACTIVITIES SUSPENDED AND NO MATERIAL RESEARCH AND DEVELOPMENT SPENDING PLANNED WHILE STRATEGIC ALTERNATIVES ARE BEING CONSIDERED..AQUINOX PHARMACEUTICALS INC - ENDED Q3 WITH $86.7 MILLION IN CASH AND CASH EQUIVALENTS.AQUINOX PHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS TOTALED $86.7 MILLION AS OF SEPTEMBER 30, 2018.AQUINOX PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.64.  Full Article

Aquinox Pharmaceuticals- Under restructuring plan announced Nov 6, co reduced workforce by 16 employees, including COO, Lloyd Mackenzie, effective Dec 31
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Aquinox Pharmaceuticals Inc ::AQUINOX PHARMACEUTICALS-UNDER RESTRUCTURING PLAN ANNOUNCED NOV 6, CO REDUCED WORKFORCE BY 16 EMPLOYEES, INCLUDING COO, LLOYD MACKENZIE, EFFECTIVE DEC 31.AQUINOX PHARMACEUTICALS SAYS ESTIMATES SECOND RESTRUCTURING PLAN, INCUR AGGREGATE RESTRUCTURING CHARGES OF ABOUT $1 MILLION IN 2018 - SEC FILING.AQUINOX PHARMACEUTICALS SAYS COMPANY IS CURRENTLY EVALUATING STRATEGIC OPTIONS.  Full Article

Aquinox Pharmaceuticals Received Notice Terminating License Agreement That Had Been Entered Between Co's Unit And Astellas US LLC
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Astellas Pharma Inc <4503.T>::AQUINOX PHARMACEUTICALS - ON SEPT 4, RECEIVED NOTICE TERMINATING LICENSE AGREEMENT THAT HAD BEEN ENTERED BETWEEN CO'S UNIT AND ASTELLAS US LLC.AQUINOX PHARMACEUTICALS INC - TERMINATION OF THE ASTELLAS AGREEMENT WILL BE EFFECTIVE MARCH 4, 2019- SEC FILING.  Full Article

Aquinox Pharmaceuticals Q2 Earnings Per Common Stock $0.12
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Aquinox Pharmaceuticals Inc ::AQUINOX PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.AQUINOX PHARMACEUTICALS INC QTRLY EARNINGS PER COMMON STOCK $0.12.AQUINOX PHARMACEUTICALS INC QTRLY REVENUE $25 MILLION.  Full Article

Ecor1 Capital Reports 7.5 Pct Passive Stake In Aquinox Pharmaceuticals
Monday, 16 Jul 2018 

July 16 (Reuters) - Aquinox Pharmaceuticals Inc ::ECOR1 CAPITAL, LLC REPORTS A 7.5 PERCENT PASSIVE STAKE IN AQUINOX PHARMACEUTICALS AS OF JULY 5, 2018- SEC FILING.  Full Article

Aquinox Pharmaceuticals Says Approved Restructuring Plan Under Which Co Reduced Its Workforce By 30 Employees
Monday, 9 Jul 2018 

July 9 (Reuters) - Aquinox Pharmaceuticals Inc ::AQUINOX PHARMACEUTICALS - ON JULY 3, APPROVED RESTRUCTURING PLAN UNDER WHICH CO REDUCED ITS WORKFORCE BY 30 EMPLOYEES AND CLOSED ITS OFFICE IN SAN BRUNO.AQUINOX PHARMACEUTICALS SAYS REGARDING RESTRUCTURING, CO ESTIMATES THAT IT WILL INCUR TOTAL RESTRUCTURING CHARGES OF ABOUT $2.5 MILLION - SEC FILING.AQUINOX PHARMA - ON JULY 3, APPROVED RESTRUCTURING PLAN AFTER JUNE 27 ANNOUNCEMENT THAT PHASE 3 LEADERSHIP 301 CLINICAL TRIAL FAILED TO MEET PRIMARY ENDPOINT.  Full Article

Aquinox Pharmaceuticals qtrly ‍net loss per share $0.50​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Aquinox Pharmaceuticals Inc -:Aquinox Pharmaceuticals announces third quarter 2017 financial results.Aquinox Pharma - ‍continues to expect that its cash-on-hand will carry it beyond top-line data from leadership 301 trial and at least to mid-2019.Aquinox Pharmaceuticals Inc - qtrly ‍net loss per common stock $0.50​.Aquinox Pharmaceuticals - ‍cash, cash equivalents, short-term, long-term investments totaled $119.7 million as of Sept 30 versus 153.1 million as of Dec 31, 2016​.  Full Article

UPDATE 2-Aquinox to stop development of lead drug; shares plunge

June 27 Aquinox Pharmaceuticals Inc said on Wednesday it planned to stop developing its main drug to treat bladder pain syndrome as it failed to meet the main goal of a late-stage trial, pushing its shares down as much as 85 percent.